HighVista Strategies has significantly increased its stake in Tyra Biosciences, purchasing 96,218 shares valued at approximately $3.11 million, according to an SEC filing dated May 15, 2026. This acquisition positions Tyra as 1.39% of HighVista’s 13F assets under management, reflecting a strategic bet on the biotech firm’s potential. Tyra’s shares have surged 280% over the past year, outperforming the S&P 500 by 250 percentage points, indicating strong market confidence in its pipeline.
The investment comes at a pivotal time as Tyra advances its clinical programs, particularly with its lead candidate, TYRA-300, targeting FGFR3 inhibition in bladder cancer. The company is also progressing in studies for other indications, with key data expected later this year. With $383.5 million in cash reserves, Tyra appears well-positioned to sustain operations and drive clinical advancements.
For investors, HighVista’s move signals confidence in Tyra’s upcoming clinical catalysts, suggesting that the company may be transitioning from a speculative biotech to a serious contender in the oncology market.
Source: fool.com